Javascript must be enabled to continue!
Patterns of Microrna in Plasma Cells: From Normal Differentiation to Multiple Myeloma
View through CrossRef
Abstract
Background: MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression either via the degradation of target mRNAs or the inhibition of protein translation. miRNAs have been involved in fine-tuning critical cellular processes and play critical roles in cell differentiation and tumor development. Furthermore, there is an increasing recognition of the role of miRNAs in multiple myeloma, a plasma cell (PC) malignancy characterized by an accumulation of malignant PCs within the bone marrow. However, little is known about miRNA expression during human PCD as well as about the full extent to which individual miRNAs regulate fundamental processes during PCD. A complete delineation of miRNA and their target expression during normal PCD is essential to understand the role of miRNAs in plasma cell malignancies.
Methods: We analyzed the expression profile of miRNAs and mRNAs during human plasma cell differentiation (PCD) to infer miRNA-target relationships, as well as in multiple myeloma tumor plasma cells. We developed a method and an R package, that uses miRNA and mRNA expression profiles across PCD cell subpopulations to infer candidate miRNA-target interactions that could be active and functional in PCD. We inferred miRNA-target relationships from sequence-based prediction, experimentally validated target interactions curated from the literature, published data from miRNA perturbation experiments and inverse expression relationships between miRNAs and their target mRNAs.
Results: Our results reveal 63 miRNAs with significant temporal changes in their expression during normal PCD. We derived a high-confidence network of 295 target relationships comprising 47 miRNAs and 147 targets. These relationships include new examples of miRNAs that are likely to coordinately regulate multiple members of critical pathways associated with PCD. Notably, we identify new miRNAs that coordinately regulate important pathways in PCD, including members of miR-30 and miR-29 families, miR-106b and miR-16, which regulates IRF4/PRDM1 axis, active DNA methylation pathway, TGF-b signaling pathway, autophagy, ZBTB4/EZH2 axis and cell cycle progression. Furthermore, our work demonstrates that 28 PCD stage-specific miRNAs are aberrantly overexpressed in multiple myeloma cells (MMCs) compared to their normal counterpart and/or are associated with high risk myeloma, suggesting that MMCs frequently acquired expression changes in miRNAs already undergoing dynamic expression modulation during normal PCD. Finally, expression of some targets of these PCD - MM miRNAs is correlated with clinical outcome of uniformly treated MM patients.
Conclusions: Altogether, our results demonstrate that miRNAs may be important in controlling PCD and malignant plasma cell biology.
Disclosures
No relevant conflicts of interest to declare.
American Society of Hematology
Title: Patterns of Microrna in Plasma Cells: From Normal Differentiation to Multiple Myeloma
Description:
Abstract
Background: MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression either via the degradation of target mRNAs or the inhibition of protein translation.
miRNAs have been involved in fine-tuning critical cellular processes and play critical roles in cell differentiation and tumor development.
Furthermore, there is an increasing recognition of the role of miRNAs in multiple myeloma, a plasma cell (PC) malignancy characterized by an accumulation of malignant PCs within the bone marrow.
However, little is known about miRNA expression during human PCD as well as about the full extent to which individual miRNAs regulate fundamental processes during PCD.
A complete delineation of miRNA and their target expression during normal PCD is essential to understand the role of miRNAs in plasma cell malignancies.
Methods: We analyzed the expression profile of miRNAs and mRNAs during human plasma cell differentiation (PCD) to infer miRNA-target relationships, as well as in multiple myeloma tumor plasma cells.
We developed a method and an R package, that uses miRNA and mRNA expression profiles across PCD cell subpopulations to infer candidate miRNA-target interactions that could be active and functional in PCD.
We inferred miRNA-target relationships from sequence-based prediction, experimentally validated target interactions curated from the literature, published data from miRNA perturbation experiments and inverse expression relationships between miRNAs and their target mRNAs.
Results: Our results reveal 63 miRNAs with significant temporal changes in their expression during normal PCD.
We derived a high-confidence network of 295 target relationships comprising 47 miRNAs and 147 targets.
These relationships include new examples of miRNAs that are likely to coordinately regulate multiple members of critical pathways associated with PCD.
Notably, we identify new miRNAs that coordinately regulate important pathways in PCD, including members of miR-30 and miR-29 families, miR-106b and miR-16, which regulates IRF4/PRDM1 axis, active DNA methylation pathway, TGF-b signaling pathway, autophagy, ZBTB4/EZH2 axis and cell cycle progression.
Furthermore, our work demonstrates that 28 PCD stage-specific miRNAs are aberrantly overexpressed in multiple myeloma cells (MMCs) compared to their normal counterpart and/or are associated with high risk myeloma, suggesting that MMCs frequently acquired expression changes in miRNAs already undergoing dynamic expression modulation during normal PCD.
Finally, expression of some targets of these PCD - MM miRNAs is correlated with clinical outcome of uniformly treated MM patients.
Conclusions: Altogether, our results demonstrate that miRNAs may be important in controlling PCD and malignant plasma cell biology.
Disclosures
No relevant conflicts of interest to declare.
Related Results
Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coronary artery disease patients
Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coronary artery disease patients
Background. Coronary artery disease (CAD) is determined by interaction of environmental factors with epigenetic and genetic factors. MicroRNA-21, microRNA-125a, microRNA-125b and m...
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Background. The protective effects of vitamin D in relation to atherogenesis are realized by vitamin D receptors (VDR). Variants rs10735810, rs731236, rs1544410 and rs797532 of the...
MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue
MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue
Purpose of the study. Determination of the expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 in colon tumor tissue depending on the...
cIg-FISH On Patients with Multiple Myeloma – A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service
cIg-FISH On Patients with Multiple Myeloma – A Modified and Simple Technique Easily Incorporated Into Routine Clinical Service
Abstract
Abstract 4792
Chromosomal abnormalities associated with unfavorable prognosis in multiple myeloma patients include involvement of the TP53, F...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
Abstract
Multiple myeloma (MM) is a malignancy of terminally differentiated clonal plasma cells displaying significant molecular heterogeneity with 7 subgroups defin...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...

